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Objective. In this paper the authors review the management of atopic dermatitis (AD) and the association between AD and allergic
respiratory diseases. Data Sources. PubMed databases, researching articles in the last 15 years. Results. Studies about atopic march
are cross-sectional population studies at diﬀerent ages. They show that the most important predisposing factor for atopy is a
decrease of the ﬁlaggrin’s expression. Conclusions. The most modern theories seem to show that the most important factor which
starts the atopic march is represented by an impaired epidermal barrier. It causes an increase in skin permeability to allergens
that could induce sensitization even in the airways. The major predisposing factor is a primary inherited epithelial barrier defect
resulting from ﬁlaggrin gene mutation, but other factors may play a role in this complex mechanism. Further studies are needed
to focus on AD treatment and preventive strategies.
1.Introduction
Atopic dermatitis (AD) is the commonest chronic cutaneous
disease of childhood in the ﬁrst years of life [1]. AD is often
the ﬁrst manifestation of allergic diseases. Literature data
[2, 3] show a progression from AD to asthma: the so-called
atopic march. In this paper we will focus reader’s attention
about the relationship between AD and respiratory allergic
diseases.
2. History of AD
AD has a long history. It was ﬁrstly described in 1892
by Besnier [4] who named it “prurigo diath´ esique”. In
order to highlight a possible association between the skin
ﬂare and genetic constitution, in 1927 Brocq suggested the
term “constitutional eczema”. Wise and Sulzberger in 1933
changed this name into “atopic dermatitis”, ﬁnally adopted
by Haniﬁn and Rajka in 1980 [5]. This is the current
denomination adopted in the USA, while in Europe the most
common deﬁnition is atopic eczema. In 2004 the World
Allergy Organisation (WAO) Committee suggested to call
“atopic eczema” any inﬂammatory condition determined
by an IgE reaction, suggesting that the presence of eczema
in atopic patients could be associated with or herald the
development of some allergic diseases such as rhinitis and
asthma [6].
3. GeneticStateof Art
AD may be the ﬁrst manifestation of allergic diseases and
may be the ﬁrst step of the so-called atopic march. Ac r u c i a l
role is played by ﬁlaggrin (ﬁlament-aggregating protein) that
is involved in the epidermal barrier function. It is important
forwaterpermeabilityandforblockingtheentryofmicrobes
and allergens [7]. Filaggrin aggregates the keratin ﬁlaments
and this process is essential for the formation of a normal
stratum corneum and for the hydration of the skin. The
ﬁlaggrin gene (FLG), located on chromosome 1q21 in
the epidermal diﬀerentiation complex, encodes proﬁlaggrin,
a phosphorylated protein, precursor of ﬁlaggrin protein.
Studies about FLG have underlined the link between early
childhood eczema and the subsequent development of
asthma. This is due to defective epidermal barrier function2 Journal of Allergy
leading to increased allergen penetration and sensitization.
Smith and coworkers in 2006 [8] demonstrated an associ-
ation between ichthyosis vulgaris and a mutation in FLG,
located on chromosome 1q21 (R501X and 2282del4).
In their study 15 families have been studied; AD was
present in 44% of individuals heterozygous for this gene
and in 76% of homozygous individuals; none of the family
member without mutation had AD. Actually it is thought
that the frequency of null FLG mutations (5 in total) is 9%
in the European population [9].
Further studies conﬁrmed both ﬁlaggrin polymorphisms
as a major risk factor for AD [10–15]. The International
Study of Asthma and Allergies in Childhood showed that in
a group of German children the presence of ﬁlaggrin variants
increased more than 3 times the risk of developing AD and
more than 2 times the risk of developing rhinitis regardless
of the presence of AD [16].
Of course, ascertaining the precise contribution of FLG
mutations to the overall prevalence of these atopic diseases
is confounded by temporal and disease severity factors in
conjunction with putative environmental eﬀects.
AD and asthma present common immunological fea-
tures, including elevated IgE levels, TH2 cytokines, lesional
and peripheral eosinophilia, and common environmental
triggers.
The hypothesis that asthma is secondary to allergic
sensitization, occurring after epidermal skin barrier disrup-
tion, has been conﬁrmed by the fact that asthma is found
only in the subset of ﬁlaggrin mutation carriers with AD,
however the precise mechanisms through which ﬁlaggrin
mutations contribute to asthma and allergic rhinitis still
remain unknown.
4. Epidemiology
Eczema is a very frequent skin disease. The prevalence of this
condition ranges from 7% to 30% in children and from 2%
to 10% in adults. In the last decades it has been increased
with a percentage double or triple higher, in the developed
countries [1].
In about 70–80% of patients, AD is associated with
increased total IgE serum levels. Atopic diseases have diﬀer-
entpeaksofincidenceatdiﬀerentagesduringchildhood.AD
and food allergies have the highest incidence in the ﬁrst 2
years of life. Sensitization to inhalant allergens is rare at that
time of life. In later childhood, the prevalence of AD, food
allergies, and food allergen sensitization decreases and the
prevalence of asthma, allergic rhinitis, and sensitization to
inhalant allergens rises [17].
Several studies have evaluated the association between
AD and respiratory allergy, in particular Kulig et al. [18]
have shown that, at the age of 5 years, 50% of children with
AD have developed allergic respiratory diseases; Ricci et al.
[19] have studied 252 children with AD, aged 6–36 months:
the mean followup of these patients was 16.9 ± 2.9y e a r s
(range 13–22 years); in the ﬁrst 10 years asthma appeared
in 34.1% of cases and RC in 57.6%; they concluded that the
severity and good control of AD was predicable for the onset
of asthma. Ohshima et al. [20]i na4 - y e a rf o l l o w - u ps t u d y
of 169 children with AD have shown that, at the end of the
study, 35% of children developed asthma. van der Hulst et
al. [21] in their systematic review have conﬁrmed that young
children with AD had a high risk of developing asthma in
later childhood.
According to a recent study by Spergel more than 50%
of children with AD may develop asthma and approximately
75% allergic rhinitis during the ﬁrst 6 years of life [3].
5.ClinicalFeatures
In AD, typical lesions of acute eczema can be observed
in a ﬁrst time, then licheniﬁcation is prevalent due to the
itching. Classically AD shows diﬀerent clinical features in
3d i ﬀerent ages: ﬁrst year of life (ﬁrst step), childhood
(second step), and adolescence/adulthood (third step). In
the ﬁrst step eczematous, exudating lesions mainly aﬀect
3/5-month-old children. Lesions are located on the scalp
and on the face where the central area is typically spared.
In more severe patients the extensor surfaces of limbs
are also involved. Parents usually refer to physician that
their babies are becoming restless and they cannot sleep at
night. In the second step ﬂexural areas of arms and legs
are commonly aﬀected. Lesions are typical of subacute or
chronic eczema, drier than those of the ﬁrst step. Children
frequently complain a bothersome itching. In the third
step patients are adolescents or adult. Furthermore in this
step they present licheniﬁed eczema usually localized in
one or a few skin areas such as the face, back of neck,
hands, wrists, and antecubital and popliteal fossae. Itching is
usually important. Inﬂammatory hyper pigmentation can be
observed in periocular and neck areas and the last has been
described as “dirty neck”. Similar lesions may be observed in
other areas as on feet.
Diagnosis of AD is not so easy [5] because of the
variety of clinical presentation, for this reason diagnostic
criteriahavebeenproposed. Theﬁrstdiagnosticcriteriawere
proposed in 1977 by Haniﬁn and Lobitz [22]; in 1980 the
diagnostic criteria by Haniﬁn and Rajka [5], were derived
from Sulzberger’s deﬁnition and from Haniﬁn and Lobitz’s
proposals. Furthermore Gu et al. reﬁned these criteria in
order to develop diagnostic guidelines for adults, children,
and nonwhite ethnic groups suﬀering of AD [23].
In 1993, a consensus report of the European Task Force
on Atopic Dermatitis [24] deﬁned a validated scale, the
SCORAD (SCORing Atopic Dermatitis), that considered
the extent and severity of the eczematous lesions and the
presence of two subjective symptoms: pruritus and loss of
sleep. Then Oranje and coworkers [25], proposed a new
SCORAD without patient’s prospective, a patient-oriented
SCORAD (PO-SCORAD) and the three-item severity (TIS)
[26] score. The TIS score ﬁts well with the more detailed
objective SCORAD and can represent both as a prescreening
system and as a useful tool for epidemiological studies.
Recently in order to validate the PO-SCORAD index, a large
European population study has been developed [27].Journal of Allergy 3
Haniﬁn et al. [28] proposed in 2001 another scoring
system named EASI (Eczema Area and Severity Index),
which can be applied to both AD children and adults. It
considered four areas of the body: the head/neck, the trunk,
and the upper and lower extremities. Each of the four
body areas was separately assessed for erythema, induration/
papulation/edema, excoriation, and licheniﬁcation. A score
ranging from 0 to 3 was used to evaluate the severity of
each sign in each of the four areas. In 2004, Charman
et al. [29] published a new, validated score used both for
adults and children called POEM (Patient-Oriented Eczema
Measure), based on patients’ assessments of what constitutes
disease severity. It consists of questions about the frequency
of seven symptoms: itch, sleep disturbance, skin bleeding,
skin weeping/oozing, skin cracking, skin ﬂaking, and skin
dryness/roughness.
IGA (Investigator Global Assessment) is another severity
score tool that has been widely used in trials consisting of
adults and children. IGA is a simple, 6-point scale, ranging
from 0 (clear) to 5 (very severe disease), representing an
overall evaluation of dermatitis that can be performed by the
investigator at every consultation [30, 31].
A recent systematic review has identiﬁed 20 diﬀerent
published outcome measures, but the authors state that only
EASI, SCORAD, and POEM have been adequately validated
and recommend using EASI or SCORAD for an objective
estimateofdiseaseseverity,plusthePOEMasameasurement
of eczema severity from the patient’s perspective [32].
IGAissurelyagoodscorebutisnotexclusiveandspeciﬁc
to AD. Numerous diﬀerential diagnoses of AD should be
considered:scabies,seborrhoeicdermatitis,Langerhanscell’s
histiocytosis mainly in childhood, and contact dermatitis in
children and adults.
6. Therapy
AD management is complex. Topical and systemic drugs are
needed to control the disease. The American Academy of
Dermatology has proposed detailed guidelines of care for
eczema [33–35] based on the assessment of clinical severity
by SCORAD or EASI indexes.
Recently, the PRACTALL (PRACTical ALLergy) con-
sensus paper proposed a simple, step-based algorithm for
eczematherapydependingontheseverity[36]:(i)dryskin:it
only needs hydration; (ii) mild, moderate, and severe eczema
require, respectively, low-, mid-, and high-potency topical
corticosteroids; furthermore topical calcineurin inhibitors
TCIs can be helpful; (iii) systemic therapy is reserved to
resistant eczema. This algorithm has some limitations: TCIs
should not be used in children under 2 years and high-
potency corticosteroids have to be avoided in children and
in special sites such as the face.
The use of TCIs has been debated, in the last few years.
In 2005 [37], the Pediatric Advisory Committee of the Food
and Drug Administration (FDA) labeled pimecrolimus and
tacrolimus as dangerous, with a black-box warning about
their potential carcinogenicity. Sporadic case of cancer set
during treatment are reported. However, several groups [38–
41] have focused on the evidence of TCIs’ carcinogenetic
role and have agreed that data are inconclusive and further
studies must be done. Furthermore recent vehicle-controlled
trials indicate eﬃcacy of proactive treatment with tacrolimus
in association with corticosteroides to prevent AE ﬂares [42]
At present however tacrolimus (Protopic) and pimecrolimus
(Elidel) ointment have to be considered second-line treat-
ments for AD in children [43].
7. AD and Qualityof Life
AD is a serious problem for patients and their families, in
fact, especially when severe, AD can be extremely disabling,
causing psychological stress that, in young children, can
involve the whole family. Clinicians should be aware of
the psychological problems related to this disease and their
impact on the child and parents’ quality of life (QOL) [44].
7.1. AD and Family Life. In 1998, Lawson et al. [45]f o c u s e d
on QOL in the families of children aﬀected by AD. They
worked out the Dermatitis Family Impact Questionnaire,
whose aim was to understand the family aspects most
inﬂuenced by the disease. Their results showed that 74%
of AD parents described a general burden of extra care,
for example, relating to household cleaning and washing,
preparing meals and shopping; 71% of parents described
psychological pressures including feelings of guilt, exhaus-
tion, frustration, resentment, and helplessness; night-time
itching and scratching caused delay in getting the child
to sleep and led to parental frustration and exhaustion in
64%. So for the 66% of families a “normal” family life
was not possible. Furthermore Lawson et al. [45]r e p o r t e d
that 63% of children with AD had current sleep problems
and most had had sleep disturbance at some time. Patients
with AD scratch more during sleep than patients with
other chronic dermatologic diseases. Pauli-Pott et al. in their
study [46] stated that mothers of children with AD were
more helpless, depressed, and overprotective than mothers
of healthy children.
Riccietal.[44]consideredtheparentsof45childrenaged
3–84 months aﬀected by AD were asked to complete two
validated questionnaires after clinical examination (Infants’
Dermatitis Quality of Life Index and Dermatitis Family
Impact questionnaire). Children’s QOL appeared slightly
moderately altered (mean score 10.2) compared with the
value of a control group (3.3), and itching, sleep problems,
and the inﬂuence of the disease on the child’s mood were
the cause of greatest discomfort for the child. Family QOL
appeared moderately altered (mean score 11) compared
with the value of the control group (7.4). The greatest
problem was the disturbed sleep of the family members.
Other important problems were the economic cost for the
management of the disease and the tiredness and irritability
caused by the disease in parents.4 Journal of Allergy
8. Conclusions
AD is a complex disease with needs a well standardized
clinical approach. Furthermore AD often preludes to other
atopic diseases. Our hope is that, in the next future, der-
matologists and paediatric allergists will have standardized
guidelines based on international consensus conferences.
Similarly to other chronic diseases such as allergic asthma,
the use of step-based therapy could be useful in the
management of the disease [4]. The evaluation of the
quality of life of patients and their families represents a new
target, with a global consideration of problems no more
limited to the skin. Although the disease mainly aﬀects
childhood, in some cases it may persist even in adulthood
and may be associated with asthma and/or allergic rhinitis.
The percentage of AD persistent cases is extremely variable,
ranging from 8–13% to 60–70% [1]. On the other hand,
healing data reported in the literature widely vary: some
authors report 50–70% healing at the age of 10 years, others
[47] 43.2% at the age of 3, and some refer to a general
improvement in AD severity in the ﬁrst 5/7 years of life
[19]. The relationship between asthma and AD is complex,
because diﬀerent and unknown mechanisms are involved
in the atopic march. Further studies about loss of function
in ﬁlaggrin gene are needed to elucidate the risks related
to epidermal barrier defects. Potential targets for barrier
repair and prevention of atopic diseases will play a crucial
role in future therapy. Much data point towards a strong
correlation between AD in early infancy and the subsequent
appearance of asthma. The risk of developing asthma in
children with AD is highly variable: according to some
authors, the prevalence is 25%, while others suggest higher
values up to 80% [17, 19]. In a recent study conducted by
our team [1], the percentages of appearance of respiratory
allergies is lower; in fact only 37.5% of children with AD
have developed respiratory pathologies (rhinoconjunctivitis
in 27% of cases and asthma alone in 17%) after a long-term
followup.Inthisstudythehigheﬃcacyreachedinpreventing
respiratory allergies has been attributed to the good control
ofADintheﬁrstyearsoflifegainedthroughtheconstantand
eﬀective collaboration between dermatologists and pediatric
allergologists, sometimes with the aid of a psychologist.
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